study to assess safety and tolerability of AZD0530 in combination with Carboplatin and Paclitaxel
Study identifier:D8180C00020
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination with Carboplatin and Paclitaxel Chemotherapy in Japanese Patients with Advanced Solid Malignancies
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD0530, Carboplatin, paclitaxel
Sex
All
Actual Enrollment
27
Study type
Interventional
Age
20 Years +
Date
Study Start Date: 01 Jan 2010
Estimated Primary Completion Date: 01 Sept 2010
Estimated Study Completion Date: 01 Mar 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Feb 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD0530 + carboplatin and paclitaxel AZD0530 in combination with carboplatin and paclitaxel | Drug: AZD0530 film coated tablet, PO, daily Drug: Carboplatin intravenous, 3 weeks Other Name: Paraplatin Drug: paclitaxel intravenous, 3 weeks Other Name: Taxol |
Contacts
Investigators
Principal Investigator
Mary Stuart
AstraZeneca
